Most patients with advanced lung adenocarcinoma can take Anrotinib, but it should be noted that it is prohibited for patients with complications such as severe bleeding, severe infection, severe hypertension, coronary heart disease and so on. The main treatments for patients with advanced lung adenocarcinoma include chemotherapy, radiotherapy, targeted drug therapy, drug-free therapy, etc. Among them, Anrotinib belongs to oral targeted therapy drugs, which is mainly used in third-line and later treatments for advanced lung adenocarcinoma, and patients with effective treatments can prolong the survival period. As a kind of anti-angiogenic targeted drug, the common adverse reactions after the use of Anrotinib include bleeding, high blood pressure, proteinuria, etc. Anrotinib is not suitable for all the patients, and there are certain contraindications to the use of the drug, therefore, its use must be guided by a professional doctor, and it can’t be taken on its own.